Brigatinib in crizotinib-refractory ALK+ NSCLC: Updated efficacy and safety results from ALTA, a randomized phase 2 trial

Authors
Category Primary study
JournalJournal of Thoracic Oncology
Year 2017
This article has no abstract
Epistemonikos ID: bc34f5890ee757bc1a1ec8b388c46a86e5fd1ce9
First added on: Feb 08, 2025